What is it about?

We discuss the decision-making frameworks for clinical trials with multiple co-primary endpoints in a group-sequential setting. The decision-making frameworks can account for flexibilities, such as a varying number of analyses, equally or unequally spaced increments of information, and fixed or adaptive Type I error allocation among endpoints. The frameworks can provide efficiency, that is, potentially fewer trial participants, than the fixed sample size designs. We investigate the operating characteristics of the decision-making frameworks and provide guidance on constructing efficient group-sequential strategies in clinical trials with multiple co-primary endpoints.

Featured Image

Read the Original

This page is a summary of: Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes, Statistics in Biopharmaceutical Research, January 2015, Taylor & Francis,
DOI: 10.1080/19466315.2014.1003090.
You can read the full text:

Read

Contributors

The following have contributed to this page